Overture Life

What happens when policy expands access faster than science can deliver it? Proposals to classify #IVF as an essential health benefit under the ACA could make fertility treatment more affordable on paper. But without addressing the nation’s shortage of embryologists and capacity-constrained lab infrastructure, new coverage could crowd an already fragile system: 430,000 cycles, 5,000 embryologists, and rising demand. The real challenge is not funding but capacity. IVF remains a highly manual, artisanal process dependent on human skill at every stage. Expanding coverage without modernizing the underlying technology risks longer wait times, higher costs, and uneven outcomes. #Automation offers a path forward. Technologies like automated piezo-ICSI and vitrification platforms can reduce manual steps, improve consistency, and open the door to more distributed care models. By strengthening the infrastructure of IVF through intelligent automation, we can make access real rather than theoretical. Overture Life CEO Hans Gangeskar writes more in MedCity News about the things the government can do to bring down the out-of-pocket costs of IVF. For example, promoting biosimilars, already available in Europe, for the cocktail of hormones needed to stimulate ovulation would reduce per-cycle costs by as much as a third. But cost isn’t the core limitation to access; it’s a symptom. If we fail to address supply constraints, government-mandated insurance coverage will become just another subsidy for insurers, without making a dent in the growing demand for IVF. https://lnkd.in/gErKTFrV

Overture Life is opening a Dallas Clinical and Operational Facility, our first U.S. laboratory and the new hub for AI-supported, non-invasive embryo testing. From this site, fertility teams will gain molecular data that helps guide embryo selection without requiring a biopsy, offering patients a safer and more consistent #IVF experience. It will also serve as Overture's U.S. clinical operations headquarters. Overture Life CEO Hans Gangeskar said: “The central U.S. location facilitates national logistics while giving us access to the biomedical engineering and data science talent concentrated in Texas.” The facility's design accommodates expanded laboratory services and continued advancement of AI-driven automation protocols, including building a continuously learning, regulated automation layer, which is the infrastructure that makes AI-driven IVF reproducible, measurable, and clinically validated. Hafsa Irfan , Head of Clinical Operations for the Dallas facility, added, “The infrastructure we're establishing here, from our non-invasive embryo assessment technology to quality systems, creates the foundation for scaling automated fertility care across the United States.” We are also hiring for positions across product development, clinical operations, laboratory operations, manufacturing, quality assurance, regulatory affairs, and commercial functions at the Dallas facility. For Dallas and the IVF community, this milestone signals a new phase where automation becomes the backbone of consistent, accessible fertility treatment. Read more in the press release: https://lnkd.in/gnhy84UN

What if IVF could be performed in more places, by more doctors, with the same precision as the best embryology labs? The Washington Post just spotlighted how #robotics and #AI are redefining fertility care. Overture Life is leading that change. Our CEO Hans Gangeskar told the Post that the real challenge isn’t just the science, but also capacity and access. With only a few thousand embryologists worldwide and millions of people struggling with infertility, #IVF remains out of reach for most. Overture’s focus is on portability. Our palm-sized DaVitri device allows OB/GYNs to safely freeze eggs in their offices, in just 15 minutes, without specialized lab infrastructure. In clinical data, 98.3% of DaVitri’s eggs survive thawing, outperforming standard methods and yielding 12% more viable embryos. As Hans put it, “Our North Star is bringing down the cost.” The future of IVF isn’t just about better technology. It’s about making family-building possible for everyone, everywhere. Read Elizabeth Dwoskin's feature here: https://lnkd.in/gJNRg6FN

Overture Life will be at the 29th #CBRA Congress in São Paulo! Join us to discover #DaVitri, the premiere automated fertility preservation platform helping fertility clinics worldwide standardize protocols and enhance operational efficiency. DaVitri is approved by ANVISA and available in Brazil. Visit our partner Spectrun Bio’s booth at Espaço L’Atelier and take part in our hands-on automated vitrification workshops to experience the future of fertility preservation in action. We look forward to connecting with you in São Paulo! --------------------------------------------- 🇧🇷 Overture Life estará presente no 29 Congresso #CBRA em São Paulo! Venha conhecer a #DaVitri, o plataforma de preservação de fertilidade automatizada que está ajudando clínicas de fertilidade em todo o mundo a padronizar protocolos e aumentar a eficiência operacional. O DaVitri é aprovado pela ANVISA e está disponível no Brasil. Visite o estande da nossa parceira Spectrun Bio, no Espaço L’Atelier, e participe das nossas demonstrações práticas de vitrificação automatizada para ver o futuro da preservação da fertilidade em ação. Estamos ansiosos para nos conectar com você em São Paulo! #CBRA2025 #InovaçãoEmFertilidade #Innovation #Vitrificação #Vitrification #Automação #Automation #OvertureLife #DaVitri

We’re launching our European pre-order waitlist for DaVitri™, the world’s first microfluidics-based automated vitrification platform. This is the start of a movement to transform how IVF is performed, delivering more consistent results through automation, as well as up to 3x higher throughput and improved blastocyst survival and outcomes. Interest from clinics across Europe is already surging. By securing a reservation, you’ll gain early access to innovation that will redefine lab workflows. Reserve your spot today: https://lnkd.in/dA3jfU-j #IVF #FertilityCare #MedTechInnovation #Microfluidics #AutomationInIVF

“To scale IVF, we have to automate what happens in the embryology lab” – Hans Gangeskar, CEO of Overture Life to NYSE’s Kristen Scholer. We announced a strategic round earlier this year to make #IVF more affordable and accessible worldwide. Our robotics platform automates critical steps from egg preparation to intracytoplasmic sperm injection (ICSI) to help clinics scale, reduce variability, and fulfill more families’ dreams of parenthood. Also discussed in this interview: – DaVitri egg-freezing device is live in Latin America, with Europe and #FDA reviews ahead. – ICSI robot piloting now at Memorial Hospital in Turkey, with a pipeline of global hospitals. IVF is healthcare at its most personal. By modernizing the embryology lab, we’re helping clinics deliver more consistent, cost-effective fertility care everywhere.  Watch the full segment: https://lnkd.in/gZ_mBhZc   #Automation #FertilityInnovation

Thanks to the The Wall Street Journal for covering the news of Matt Combs Joining us as Chief Commercial Officer. https://lnkd.in/eJKhnRPk

Overture Life invites you to see their automated fertility preservation platform at ESHRE 2025 in Paris:

The Overture Life team is thrilled to be participating in this year’s European Society of Human Reproduction and Embryology (ESHRE) meeting and showcasing our latest advancements in reimagining fertility services through automation, precision, and scale. We invite you to discover #DaVitri, the world’s premiere automated fertility preservation platform. Whether you're a clinician, embryologist, or innovator, this is your chance to experience firsthand how automation is transforming reproductive medicine. 🔎 Here are three ways to experience DaVitri at ESHRE: 🔸 Visit us at Booth A044 – Get hands-on with the device and connect with our team. 🔸 Attend our Oral Presentation – July 2 at 11:00 AM | Session 75 “Automated oocyte vitrification with the DaVitri device: a prospective study on survival and blastulation.” 🔸 Book a Private Showing – Reach out to us at info@overture.life See you all in Paris! #ESHRE2025 #FertilityInnovation #AutomationInIVF #ReproductiveTech #DaVitri #OvertureLife